Vir Biotechnology/$VIR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Ticker

$VIR
Sector
Primary listing

Employees

408

VIR Metrics

BasicAdvanced
$814M
-
-$4.01
1.28
-

What the Analysts think about VIR

Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.

Bulls say / Bears say

Vir Biotechnology successfully dosed the first patient in its ECLIPSE Phase 3 chronic hepatitis delta program in March 2025, a trial granted U.S. FDA Breakthrough and Fast Track designations as well as EMA PRIME and Orphan Drug designations to expedite development (Nasdaq)
Early Phase 1 data for its PRO-XTEN™ dual-masked T-cell engagers showed tumor shrinkage in 50% of participants with HER2-positive solid tumors (VIR-5818) and PSA reductions in 100% of mCRPC patients with 58% achieving PSA50 (VIR-5500), validating its oncology platform’s potential (Nasdaq)
As of March 31, 2025, Vir held approximately $1.0 billion in cash and investments, providing a projected financial runway into mid-2027 to support its key clinical and preclinical programs (Nasdaq)
Total revenue plummeted 95% year-over-year to $3.03 million in Q1 2025, driven by the expiration of GSK collaboration rights and underscoring a lack of recurring revenue sources (Nasdaq)
Vir’s net loss widened to $0.88 per share in Q1 2025 from $0.48 a year earlier, reflecting an 85% increase in losses and intensifying funding requirements (Nasdaq)
Net cash used in operating activities remained high at $78 million in Q1 2025 despite minimal revenue, accelerating cash burn that could truncate its mid-2027 runway if programs face setbacks (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.

VIR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VIR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VIR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Vir Biotechnology stock | $VIR Share Price | Lightyear